11-Hydroxy-3,20-dioxo-21-sulfanylpregn-4-en-17-yl butanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 11-Hydroxy-3,20-dioxo-21-sulfanylpregn-4-en-17-yl butanoate
• 英文别名: [11-hydroxy-10,13-dimethyl-3-oxo-17-(2-sulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] butanoate
• 化学式: C₂₅H₃₆O₅S
• 分子量: 448.6
• InChiKey: HOAKOHHSHOCDLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  81.7
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] METHOD FOR THE TREATMENT OF A RESPIRATORY DISEASE, DISORDER, OR CONDITION RESULTING FROM A VIRAL INFECTION<br/>[FR] MÉTHODE DE TRAITEMENT D'UNE MALADIE, D'UN TROUBLE OU D'UN ÉTAT RESPIRATOIRE PROVENANT D'UNE INFECTION VIRALE
  申请人：SOFTHALE NV

  公开号：WO2021180919A1

  公开（公告）日：2021-09-16

  The present invention provides for a method for the treatment of a respiratory disease, disorder, or condition resulting from a viral infection in a subject, such as a pulmonary viral infection, the method comprising the step of administering to said subject a medically active liquid in nebulized form by inhalation, wherein the medically active liquid comprises an inhalable corticosteroid (ICS) and wherein the medically active liquid is administered in nebulized form using an inhalation device.